Company Overview - Galecto, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for hematological cancers [3] - The company's pipeline includes a mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis [3] - Galecto is also advancing GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for treating multiple genetic subsets of acute myeloid leukemia [3] Equity Awards Announcement - On March 2, 2026, Galecto granted equity awards to four newly-hired, non-executive employees as material inducements for their acceptance of employment [1] - The inducement grants consist of non-qualified stock options to purchase a total of 153,700 shares of Galecto's common stock, with a 10-year term and an exercise price of $29.58 per share [2] - The options will vest 25% on the first anniversary of the grant date and in equal monthly installments over the following 36 months [2]

Company Overview - Galecto, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for hematological disorders [3] - The company's pipeline includes a mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis [3] - Galecto is also advancing GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for treating multiple genetic subsets of acute myeloid leukemia [3] Upcoming Events - Company management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026, at 10:40 a.m. ET [1] - A live webcast of the presentation will be available on the company's website, with an archived replay accessible for 30 days post-event [2]

Company Overview - Galecto, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for blood cancers, including a portfolio targeting essential thrombocythemia and myelofibrosis [5] - The company's pipeline features GB3226, a first-in-class preclinical dual inhibitor aimed at treating multiple genetic subsets of acute myeloid leukemia [5] Recent Financial Activity - Galecto announced the closing of an underwritten public offering of 16,644,737 shares of common stock at a public offering price of $19.00 per share, resulting in gross proceeds of approximately $316.3 million before expenses [1] - The offering included the full exercise of the underwriters' option to purchase an additional 2,171,052 shares [1] Underwriters and Registration - Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities served as joint book-running managers for the offering [2] - An automatically effective shelf registration statement was filed with the SEC on February 10, 2026, and the offering was conducted via a written prospectus [3]

Core Viewpoint - Galecto, Inc. has announced a public offering of 14,473,685 shares of common stock at a price of $19.00 per share, aiming to raise approximately $275 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 2,171,052 shares at the same public offering price [1]. - The expected closing date for the offering is around February 12, 2026, subject to customary closing conditions [2]. Group 2: Company Overview - Galecto, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for hematological cancers [5]. - The company's pipeline includes a mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio and GB3226, a first-in-class preclinical dual inhibitor for acute myeloid leukemia [5].

Core Viewpoint - Galecto, Inc. has initiated an underwritten public offering of its common stock and Series C non-voting convertible preferred stock to support its therapeutic development for blood cancers [1][2]. Group 1: Offering Details - The public offering includes common stock and Series C preferred stock, with the latter convertible into 1,000 shares of common stock at the holder's discretion [1]. - Galecto plans to grant underwriters a 30-day option to purchase additional shares of common stock [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1]. Group 2: Use of Proceeds - Proceeds from the offering will be utilized for preclinical studies, clinical trials, manufacturing for antibody programs, and additional research and development activities [2]. - Funds will also support working capital and general corporate purposes [2]. Group 3: Management and Registration - Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are acting as joint book-running managers for the offering [3]. - An automatically effective shelf registration statement was filed with the SEC on February 10, 2026, and the offering will be conducted via a written prospectus [4]. Group 4: Company Overview - Galecto, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for hematological cancers [6]. - The company's pipeline includes a mutant calreticulin-driven myeloproliferative neoplasm portfolio and GB3226, a preclinical dual inhibitor for acute myeloid leukemia [6].

Core Insights - Galecto, Inc. is advancing its pipeline with a focus on mutant calreticulin (mutCALR) targeting monoclonal antibodies, specifically DMR-001 and DMR-002, with IND submissions expected in mid-2026 and the second half of 2026 respectively [1][11] - The company has recently expanded its management team, enhancing its capabilities in hematology and oncology drug development [2][5][6] Company Strategy and Milestones - 2026 is anticipated to be a pivotal year for Galecto, with the initiation of clinical development for its anti-mutCALR pipeline candidates [4] - DMR-001 is designed to address a wide range of CALR mutations in essential thrombocythemia (ET) and myelofibrosis (MF), demonstrating potent activity in preclinical models [4][7] - The company plans to submit an IND for DMR-001 by mid-2026, with first-in-human dosing expected to follow [1][7] Financial Position - Galecto raised $285 million in a PIPE financing in November, providing a financial runway into 2029 to support multiple data milestones, including Phase 1 clinical proof-of-concept data for DMR-001 anticipated in 2027 [5][8] Management Team Expansion - Sherwin Sattarzadeh has been appointed as Chief Operating Officer, bringing over 20 years of experience in drug development [6] - Becker Hewes has been appointed as Chief Medical Officer, with a strong background in hematology/oncology drug development [6] Pipeline Overview - In addition to DMR-001, DMR-002 is also in development, with an IND submission planned for the second half of 2026 [11] - GB3226, a dual inhibitor for acute myeloid leukemia (AML), is expected to have its IND submission in the first quarter of 2026 [11]

Core Insights - Galecto, Inc. has appointed Sherwin Sattarzadeh as Chief Operating Officer and Dr. Becker Hewes as Chief Medical Officer, enhancing its leadership team for advancing drug development in hematology/oncology [1][2][3] Leadership Appointments - Sherwin Sattarzadeh brings over 20 years of experience in drug development, previously serving as Chief Business Officer at Blueprint Medicines, with a strong background in hematology/oncology [2][3] - Dr. Becker Hewes has over two decades of experience in drug development, having led significant projects at Blueprint Medicines, including the approval of AYVAKIT for systemic mastocytosis [3] Product Development - DMR-001, a monoclonal antibody targeting mutant calreticulin (mutCALR), is on track for IND submission in mid-2026, with first-in-human dosing expected to occur via subcutaneous administration [1][7] - DMR-001 has shown potent activity in preclinical models for both essential thrombocythemia (ET) and myelofibrosis (MF), indicating its potential as a best-in-class treatment [7] Financial Position - The company has a cash balance that includes $285 million raised in a PIPE transaction in November 2025, providing financial runway into 2029 to support multiple data milestones, including Phase 1 clinical proof-of-concept data for DMR-001 anticipated in 2027 [1] Compensation and Incentives - The company approved significant stock options and restricted stock units for both Sattarzadeh and Hewes as part of their inducement grants, aligning their interests with the company's long-term success [4][5]

Core Viewpoint - Galecto, Inc. has granted non-qualified stock options to a new employee as part of its 2022 Inducement Plan, which is a strategic move to attract talent in the biotechnology sector [1][2]. Company Overview - Galecto, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for hematological cancers, with a specific emphasis on mutant calreticulin-driven myeloproliferative neoplasms [3]. - The company is preparing to submit an Investigational New Drug (IND) application for its lead asset, DMR-001, which targets mut-CALR and is expected to be filed in mid-2026 [3]. - Galecto's pipeline also includes GB3226, a first-in-class preclinical dual inhibitor aimed at treating various genetic subsets of acute myeloid leukemia (AML) [3].

Core Insights - Galecto Inc. (NASDAQ:GLTO) stock experienced a significant increase, tripling in value on Monday with a trading volume of 23.26 million shares, compared to the average volume of 2.41 million shares [1] - The company acquired Damora Therapeutics, which specializes in antibody therapeutics for mutant calreticulin-driven myeloproliferative neoplasms, enhancing its pipeline in hematological cancers [1][2] Company Developments - The acquisition of Damora Therapeutics broadens Galecto's pipeline, allowing it to advance complementary assets targeting blood cancers [2] - A private placement led by Fairmount raised approximately $284.9 million for Galecto, expected to fund operations through 2029 and support the advancement of Damora's lead program, DMR-001, with key Phase 1 proof-of-concept data anticipated in 2027 [3] Pipeline and Regulatory Updates - An Investigational New Drug (IND) submission for DMR-001 is expected in mid-2026, with plans for first-in-human subcutaneous administration [4] - Galecto aims to combine the newly acquired assets with its investigational candidate GB3226, a dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia (AML) [4] - The company received constructive feedback from the U.S. FDA on its pre-IND submission and plans to submit an IND application for GB3226 in the first quarter of 2026 [5] Stock Performance - Following these developments, GLTO stock rose by 293.33%, reaching $19.40 [5]

Summary of Conference Call Regarding Galecto's Acquisition of Demora Therapeutics Industry and Company Involved - **Industry**: Biotechnology, specifically focusing on hematological cancers and myeloproliferative neoplasms (MPNs) - **Companies**: Galecto Incorporated and Demora Therapeutics Core Points and Arguments 1. **Acquisition Announcement**: Galecto has announced the acquisition of Demora Therapeutics, which is expected to create significant value and expand Galecto's pipeline with Demora's anti-mutant calreticulin targeted therapies [4][5] 2. **Pipeline Expansion**: The acquisition will enhance Galecto's existing programs, particularly in the treatment of hematological cancers, by integrating Demora's portfolio of potentially best-in-class antibodies [4][5] 3. **Financial Backing**: Over $285 million was raised in an oversubscribed private financing, which is anticipated to fund the combined company's lead programs, including DMR 001, extending the cash runway beyond key phase one proof of concept data expected in 2027 [5] 4. **Market Opportunity**: There are over 42,000 patients with calreticulin mutant MPNs in the U.S., representing a potential market opportunity exceeding $5 billion [9] 5. **Lead Asset - DMR 001**: DMR 001 is designed to target mutant calreticulin and is expected to enter first-in-human trials by mid-2026, with clinical proof of concept readouts anticipated in mid-2027 [8][10] 6. **Clinical Development**: DMR 001 has shown increased binding affinity and inhibition of calreticulin-driven cell proliferation in preclinical studies, with a tenfold increase in potency against type 2 mutant cells [10] 7. **Convenience of Administration**: DMR 001 is engineered for low-volume subcutaneous administration, which is crucial for patients requiring long-term therapy [10] 8. **Future Developments**: Additional assets in the pipeline include DMR 002 and DMR 003, with IND filings expected in the second half of 2026 [11] Other Important Content 1. **Management's Forward-Looking Statements**: The call included forward-looking statements regarding the potential benefits of the acquisition and future expectations for the combined company, emphasizing the inherent risks and uncertainties [2][3] 2. **Board Expansion**: New board members Julie Bruno, Chris Kane, and Peter Howan were welcomed, indicating a strengthening of governance and expertise as the company enters a new phase [5] 3. **Clinical Focus**: The focus on MPNs, particularly essential thrombocythemia and myelofibrosis, highlights the unmet medical need in this area, as there are currently no available disease-modifying therapies [4][8]